In a recent move, Novo Nordisk has transferred its experimental Parkinson’s disease cell therapy program to Cellular Intelligence, a biotech startup backed by Mark Zuckerberg. The deal marks a shift in focus for Novo, which had been developing a stem-cell-based treatment called STEM-PD before shutting down its cell-therapy unit last year. The transfer allows Cellular Intelligence to leverage its artificial intelligence platform to accelerate the therapy’s development.

Details of the Transition

Although financial terms were not disclosed, Novo Nordisk is taking an equity stake in Cellular Intelligence and stands to receive future milestone payments and royalties. The therapy, STEM-PD, was designed to replace dopamine-producing nerve cells lost in Parkinson’s patients. It was in early clinical stages at Novo before the company decided to wind down its cell-therapy operations during a broader restructuring.

Cellular Intelligence plans to use its AI tools to speed up the therapy’s progress, improve manufacturing processes, and lower costs. The startup has already raised over $60 million from investors including Khosla Ventures and the Chan Zuckerberg Initiative. This move aligns with CZI’s recent investments in AI-driven biological research, reflecting a broader trend of tech and biotech convergence.

Implications for Parkinson’s Treatment and Industry

Parkinson’s affects around 10 million people worldwide, and treatments that replace lost dopamine-producing cells have been pursued for decades. Cellular Intelligence’s approach aims to make such therapies more viable by using AI to optimize manufacturing and dosing, potentially shortening the timeline for bringing a treatment to market.

For Novo Nordisk, the deal closes a chapter on its early-stage cell therapy efforts, which were not yet commercial. The company has shifted its focus to its core areas of obesity and diabetes, notably with the success of drugs like Wegovy and Ozempic. The discontinuation of the cell therapy unit freed up manufacturing capacity for these more profitable treatments.

Cellular Intelligence’s strategy combines an established therapy candidate with its AI platform’s capabilities to attract investor interest. While the timeline for future clinical milestones remains unclear, the company’s positioning suggests it intends to demonstrate the cost and speed advantages of AI-assisted drug development.

Overall, this partnership highlights how AI is transforming biotech research, especially in complex fields like regenerative medicine. By combining existing therapies with advanced data tools, startups hope to overcome traditional hurdles in cell therapy development, potentially offering new hope for patients with Parkinson’s and other neurodegenerative diseases.

Inspired by

• https://thenextweb.com/news/novo-nordisk-cellular-intelligence-stem-pd-parkinsons

Sources

• cnbc.com